OncoMethylome Sciences

OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - January 23, 2009, 18:00 PM CET- OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that Mr. Gerard Vaillant will join its Board of Directors as a replacement to Dr. Christian Schneider, and that Mr. Gert-Jan Renardel de Lavalette has been hired as Chief Operating Officer.

OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - December 19, 2008, 11:55 AM CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that the capital increase of EUR 8.4 million as announced on December 16, 2008, has been completed and that the 1,332,877 new shares will be admitted to trading on Euronext Brussels and Euronext Amsterdam on December 19, 2008. A prospectus relating to the admission to listing of these shares will be made available on the company's website as from December 19, 2008.

OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - December 16, 2008, 9:30 AM CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that it has agreed to issue 1,332,877 new shares in a private placement for a total amount of EUR 8.4 million. These extra funds will be used to expand OncoMethylome's biomarker development for pharmaceutical applications, such as companion diagnostic tests used in personalized treatment of cancer patients. AGF Private Equity (member of the Allianz insurance group), APG Investments (world's 3rd largest pension fund) and Fortis Investments Management purchased the newly issued OncoMethylome common shares in a private placement. The new shares will be issued at a price of EUR 6.29 per share and will represent 10.1% of the new total of 13,161,074 outstanding OncoMethylome shares. As a result of this transaction, AGF Private Equity acquired 6.0% of the shares of OncoMethylome, and APG Investments and Fortis eac ...

OncoMethylome Sciences (EBR:ONCOB) OncoMethylome's MGMT gene methylation technology provides oncologists with a new tool to guide patient care

OncoMethylome Sciences (EBR:ONCOB) Liège, Belgium - November 12, 2008, 08.00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has signed a world-wide, non-exclusive license agreement with QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA). Under this agreement, QIAGEN has licensed certain of OncoMethylome's methylation technologies for use in certain of QIAGEN's future products. These products will expand, among others, QIAGEN's EpiTect product line. The agreement specifically covers the use of OncoMethylome's patented Methylation-Specific PCR (MSP) technology, the most widely applied epigenetic technology, for the scientific research market. Under the terms of the agreement, QIAGEN will pay OncoMethylome an upfront fee plus royalties from future sales of products utilizing this technology. Other terms of the agreement were not disclosed.

OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - November 6, 2008, 08.00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), an innovative molecular diagnostics company, today issued its Q3 2008 business update, providing an overview of its financial position and summarizing material events that took place during this period.

OncoMethylome Sciences (EBR:ONCOB) LabCorp presents positive results on GST-Pi/APC methylation test for detection of prostate cancer OncoMethylome's methylation technology for improving the detection of prostate cancer was validated in a study presented by LabCorp.

OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - Regulatory Release - September 12, 2008, 8:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) publishes required information in accordance with new transparency legislation (Belgian Act of May 2, 2007) on disclosure of major holdings in issuers whose shares are admitted to trading on a regulated Belgian market.

OncoMethylome Sciences (EBR:ONCOB) First Methylation Tests are Launched and Available to Cancer Patients

OncoMethylome Sciences OncoMethylome's methylation detection technology is used in the new ColoSureTM colorectal cancer screening assay